Reply to "Performance of risk models in predicting outcomes of atezolizumab and bevacizumab therapy"
Related Experiment Video
Updated: Mar 4, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Masayuki Ueno1,2, Atsushi Takai3, Hiroshi Seno1
1Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
No abstract available in PubMed .
More Related Videos
06:19Constructing and Visualizing Models using Mime-based Machine-learning Framework
Published on: July 22, 2025
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Cancer Survival Analysis
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions